Secukinumab demonstrates high and sustained efficacy in nail psoriasis: post hoc analysis from phase III trials in patients with psoriatic arthritis

Kristian Reich; Xenophon Baraliakos; Laura C Coates; Boni Elewski; Weibin Bao; Torben Kasparek; Corine Gaillez; Effie Pournara; Maher Aassi; Chiara Perella; Alice B Gottlieb

doi:10.1111/bjd.21233

Secukinumab demonstrates high and sustained efficacy in nail psoriasis: post hoc analysis from phase III trials in patients with psoriatic arthritis

Kristian Reich
Xenophon Baraliakos
Laura C Coates
Boni Elewski
Weibin Bao
Torben Kasparek
Corine Gaillez
Effie Pournara
Maher Aassi
Chiara Perella
Alice B Gottlieb

Related Research units

Institute for Health Services Research in Dermatology and Nursing

Abstract

Secukinumab showed consistent and sustained efficacy in clearing nail psoriasis in patients with psoriatic arthritis, with or without axial manifestations, irrespective of severity of nail involvement. Reduction of nail disease was also associated with response across all musculoskeletal and skin manifestations of psoriatic arthritis.

Bibliographical data

Original language	English
ISSN	0007-0963
DOIs	https://doi.org/10.1111/bjd.21233
Publication status	Published - 09.2022

Comment Deanary

PubMed	35257363